Many patients with celiac disease have other medical conditions, such as co-occurring autoimmune disorders, requiring treatment with prescription medications. There are also several investigational treatments for celiac disease currently in the drug development pipeline that we are hopeful will be available to patients in the coming years. For these reasons, we support improved insurance coverage and affordable access to prescription drugs.

On May 11, 2018, the Trump Administration issued the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs with a corresponding Request for Information (RFI) from patient groups and advocates, health care providers, drug manufacturers, insurance plans, and other stakeholders on May 16, 2018.

The American Autoimmune Related Diseases Association (AARDA), an organization dedicated to the eradication of autoimmune diseases and the alleviation of suffering and the socioeconomic impact of autoimmunity, submitted an RFI comment letter to the Department of Health and Human Services on July 16, 2018. As a member of the National Coalition of Autoimmune Patients (NCAPG), a coalition founded by AARDA, the Celiac Disease Foundation signed onto AARDA’s RFI comment letter July 13, 2018.


Stay informed. Click here to get updates on the latest developments in advocacy, research news, events, and more from the Celiac Disease Foundation.

Celiac Disease Foundation Signs Letter Advocating for Improved Coverage & Affordable Access to Prescription Drugs